For example, clinical guidelines recommend that patients with early stage breast cancer with overexpression of human epidermal growth factor-like receptor No 2 (HER-2) receive trastuzumab [7], and erlotinib is recommended for epidermal growth factor receptor (EGFR) mutation positive nonsquamous non-small cell lung cancer [8]. This evidence concerns the gene EGFR and breast carcinoma.